Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 May;206(5):1366-1372.
doi: 10.1111/bjh.19978. Epub 2025 Jan 5.

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse

Cyrille Touzeau  1   2   3 , Xavier Leleu  4 , Mourad Tiab  5 , Margaret Macro  6 , Aurore Perrot  7 , Julie Gay  8 , Carine Chateleix  9 , Stéphane Moreau  10 , Lionel Karlin  11 , Caroline Jacquet  12 , Salomon Manier  13 , Cyrille Hulin  14 , Olivier Decaux  15 , Valentine Richez  16 , Thomas Chalopin  17 , Mohamad Mohty  18 , Frédérique Orsini-Piocelle  19 , Denis Caillot  20 , Cécile Sonntag  21 , Marguerite Vignon  22 , Arthur Bobin  4 , Hervé Avet-Loiseau  7 , Alexandra Jobert  23 , Lucie Planche  23 , Jill Corre  7 , Philippe Moreau  1   2   3
Affiliations
Clinical Trial

Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse

Cyrille Touzeau et al. Br J Haematol. 2025 May.

Abstract

Most transplant-ineligible patients present with multiple myeloma (MM) refractory to lenalidomide and/or anti-CD38 monoclonal antibody at first relapse and represent a difficult-to-treat population. The Intergroupe Francophone du Myélome phase 2 study iberdomide, ixazomib and dexamethasone (I2D) evaluated the oral triplet iberdomide, ixazomib and dexamethasone in MM patients aged ≥70 years at first relapse (NCT04998786). Seventy patients were enrolled to receive iberdomide (1.6 mg on day 1-21), ixazomib (3 mg on day 1, 8, 15) and dexamethasone (20 mg on day 1, 8, 15, 22 on cycle 1-2 and 10 mg on day 1, 8, 15, 22 on cycle 3-6) (28-day cycle) until disease progression. Median age was 76; 50% patients were frail according to the International Myeloma Working Group frailty score; 74% and 37% were refractory to lenalidomide and daratumumab respectively. With a median follow-up of 14 months, the overall response rate was 64%, including 36% very good partial response or better. The 12-month progression-free survival, duration of response and overall survival were 52%, 76% and 86% respectively. The most common (46%) grade 3-4 toxicity was neutropenia. Non-haematological adverse events were mostly grade 1 or 2. Overall, I2D demonstrated a favourable risk-benefit profile in elderly MM patients at first relapse, including in patients with lenalidomide and daratumumab refractory disease.

Keywords: elderly; iberdomide; ixazomib; myeloma.

PubMed Disclaimer

References

REFERENCES

    1. Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem‐cell transplant (SWOG S0777): a randomised, open‐label, phase 3 trial. Lancet. 2017;389:519–527.
    1. Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380:2104–2115.
    1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple myeloma: EHA‐ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. HemaSphere. 2021;5:e528.
    1. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2019;20:781–794.
    1. Matyskiela ME, Zhang W, Man H‐W, Muller G, Khambatta G, Baculi F, et al. A cereblon modulator (CC‐220) with improved degradation of Ikaros and Aiolos. J Med Chem. 2018;61:535–542.

Publication types

MeSH terms